Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed EKF Diagnostics (LON:EKF) announced that performance has been ahead of management expectations despite currency headwinds. Net cash at 30th June was £9 million, £5 million ahead of last year despite significant operational investment.
The company signed three major distribution contracts in the US during the first half which should improve its positioning in that market, particularly within the diabetes sector. One new product has received US Food and Drug Administration clearance and a second has been submitted for approval.
Shares in EKF rose by 2.78% to 39.48p (as of 13:15 BST).